Home Data Calendar Blog

XNCR

Tables

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Common Stock Value		0.70	0.62	0.62	0.61	0.61	0.61	0.60	0.60	0.60	0.60	0.60	0.59	0.58	0.58	0.58	0.58	0.57	0.57	0.57	0.57	0.57	0.56	0.56	0.56	0.56	0.47	0.47	0.47	0.47
Weighted Average Number Of Diluted Shares Outstanding		64.02	61.68	61.21	NA	60.62	59.81	59.77	NA	59.72	59.57	61.08	NA	NA	NA	NA	NA	57.27	57.06	56.95	NA	56.64	56.40	58.01	NA	58.31	NA	46.93	46.77	NA
Weighted Average Number Of Shares Outstanding Basic		64.02	61.68	61.21	NA	60.62	59.81	59.77	NA	59.72	59.57	59.41	NA	NA	NA	NA	NA	57.27	57.06	56.95	NA	56.64	56.40	56.30	NA	55.97	NA	46.93	46.77	NA
Earnings Per Share Basic		-0.71	-1.07	-1.11	-0.31	-0.40	-0.37	-1.02	-0.21	-0.55	-0.57	0.40	1.26	-0.69	0.90	-0.04	-0.24	-0.22	-0.61	-0.14	-0.47	-0.18	-0.28	1.42	-0.32	0.06	-0.25	-0.33	-0.15	-0.31
Earnings Per Share Diluted		-0.71	-1.07	-1.11	-0.31	-0.40	-0.37	-1.02	-0.21	-0.55	-0.57	0.39	1.21	-0.69	0.87	-0.04	-0.24	-0.22	-0.61	-0.14	-0.47	-0.18	-0.28	1.38	-0.32	0.05	-0.25	-0.33	-0.15	-0.31

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Revenue From Contract With Customer Excluding Assessed Tax		10.71	16.96	12.80	44.69	59.16	45.52	18.96	21.61	27.30	30.18	85.50	154.01	19.68	67.45	33.97	41.85	35.37	13.09	32.38	3.52	21.76	19.48	111.94	11.56	29.04	30.15	0.00	12.50	3.50
Revenues		10.71	16.96	12.80	44.69	59.16	45.52	18.96	21.61	27.30	30.18	85.50	154.01	19.68	67.45	33.97	41.85	35.37	13.09	32.38	3.52	21.76	19.48	111.94	11.56	29.04	30.15	0.00	12.50	3.50
Operating Expenses		72.99	79.28	70.66	79.70	77.43	71.52	78.33	64.20	65.65	58.17	59.03	62.36	60.98	58.36	49.64	55.55	52.09	50.69	41.16	34.09	36.04	39.06	33.70	32.65	28.39	24.82	23.58	21.01	19.86
Research And Development Expense		58.23	61.53	56.87	64.22	64.94	60.06	64.38	51.45	53.27	47.08	47.76	50.99	50.61	49.50	41.41	47.95	44.45	43.46	33.94	27.34	29.77	33.30	28.18	27.13	20.95	20.40	19.41	16.92	15.05
General And Administrative Expense		14.77	17.75	13.79	15.48	12.49	11.46	13.95	12.75	12.37	11.09	11.27	11.38	10.37	8.86	8.23	7.60	7.64	7.23	7.22	6.75	6.27	5.76	5.51	5.52	7.43	4.43	4.17	4.09	4.81
Operating Income Loss		-62.28	-62.32	-57.85	-35.01	-18.27	-26.00	-59.37	-42.59	-38.35	-28.00	26.47	91.65	-41.30	9.09	-15.67	-13.70	-16.72	-37.60	-8.78	-30.57	-14.28	-19.57	78.24	-21.08	0.65	-13.88	-16.49	-7.67	-15.52
Interest Paid Net		0.01	0.01	0.01	0.00	0.01	0.01	0.01	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.01	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.00	0.00	0.00
Income Tax Expense Benefit		0.00	0.12	NA	NA	NA	NA	NA	-0.41	1.09	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.29	-0.35	0.05	0.90	NA	NA	-1.09	0.17	0.28	0.17
Income Taxes Paid Net		0.00	NA	NA	NA	NA	NA	NA	0.63	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.20	0.05	NA	NA	0.06	0.00	0.18	0.73	0.00	0.06
Profit Loss		-46.30	-67.41	-68.71	-19.26	-24.27	-21.95	-60.76	-12.04	-32.76	-33.97	23.59	73.06	-40.19	52.25	-2.49	-13.69	-12.55	-35.02	-8.07	-26.91	-10.22	-16.03	80.05	-18.20	3.15	-11.84	-15.56	-6.04	-15.47
Net Income Loss		-45.14	-65.96	-68.03	-19.10	-24.27	-21.95	-60.76	-12.04	-32.76	-33.98	23.59	73.06	-40.19	52.25	-2.49	-13.69	-12.55	-35.02	-8.07	-26.91	-10.22	-16.03	80.05	-18.20	3.15	-11.84	-15.56	-6.88	-14.63
Comprehensive Income Net Of Tax		-42.69	-66.46	-69.48	-17.10	-23.12	-20.19	-57.44	-9.12	-33.69	-35.80	17.98	71.63	-40.25	52.14	-2.46	-14.18	-13.47	-34.59	-8.18	-27.19	-10.42	-14.75	81.36	-16.83	2.82	-12.55	-15.42	-6.93	-14.39
Net Income Loss Available To Common Stockholders Basic		-45.14	-65.96	-68.03	-19.10	-24.27	-21.95	-60.76	-12.04	-32.76	-33.98	23.59	73.06	-40.19	52.25	-2.49	-13.69	-12.55	-35.02	-8.07	-26.91	-10.22	-16.03	80.05	-18.20	3.15	-3.07	-22.65	-7.72	-15.47

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Assets		983.63	826.17	884.25	952.69	778.43	778.12	803.41	846.27	835.27	851.33	857.92	838.21	697.26	695.60	692.74	703.24	646.35	644.72	666.96	670.25	686.24	684.75	697.00	576.73	585.59	390.10	398.25	416.16	418.30
Liabilities		262.74	263.63	272.07	283.56	109.42	99.25	119.83	118.77	112.57	108.98	94.90	104.71	78.40	48.66	109.12	130.80	77.87	74.08	73.96	77.05	76.01	76.66	87.44	55.05	53.31	108.06	107.72	114.80	114.56
Liabilities And Stockholders Equity		983.63	826.17	884.25	952.69	778.43	778.12	803.41	846.27	835.27	851.33	857.92	838.21	697.26	695.60	692.74	703.24	646.35	644.72	666.96	670.25	686.24	684.75	697.00	576.73	585.59	390.10	398.25	416.16	418.30
Stockholders Equity		723.84	564.33	612.53	668.80	669.01	678.88	683.58	727.50	722.70	742.34	763.02	733.50	618.86	646.94	583.61	572.44	568.48	570.64	593.00	593.20	610.24	608.09	609.57	521.68	532.27	282.05	290.54	301.37	303.75

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Assets Current		573.33	554.47	562.25	623.16	571.18	593.56	629.98	675.34	668.00	585.94	505.97	424.37	329.63	480.97	591.17	637.67	570.88	603.39	588.11	558.40	573.76	527.01	488.67	315.73	286.92	230.88	217.81	210.98	166.09
Cash And Cash Equivalents At Carrying Value		29.03	30.77	31.03	53.79	52.73	34.71	72.39	53.94	52.65	49.41	78.27	143.48	41.20	115.84	176.97	163.54	58.09	109.53	73.81	50.31	51.19	32.56	21.86	26.25	35.00	16.53	13.63	11.22	13.56
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		29.42	31.15	31.42	54.17	53.11	34.71	72.39	53.94	52.65	49.41	78.27	143.48	41.20	115.84	176.97	163.54	58.09	109.53	73.81	50.31	51.19	32.56	21.86	26.25	35.00	16.53	13.63	11.22	NA
Accounts Receivable Net Current		10.21	22.07	9.58	11.29	55.00	20.02	19.86	29.00	44.88	54.28	88.20	66.38	20.55	14.82	12.53	11.44	9.53	8.93	6.83	21.57	4.35	10.13	137.68	10.19	2.46	1.14	0.83	14.88	6.94
Prepaid Expense And Other Assets Current		20.15	23.99	16.74	18.14	21.64	22.17	22.09	23.28	22.89	19.73	23.01	23.88	20.88	15.59	14.16	10.73	10.19	7.40	6.48	6.55	7.53	11.31	9.43	10.38	12.10	5.61	7.03	7.62	4.37
Equity Securities Fv Ni		78.90	28.27	44.53	42.21	28.97	39.99	39.71	42.43	32.18	26.89	33.43	36.86	47.58	45.23	6.14	5.30	5.38	2.61	2.25	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Available For Sale Securities Debt Securities		725.32	554.23	615.33	643.24	433.25	NA	475.92	530.51	557.12	576.04	517.09	454.23	476.17	442.60	393.96	435.19	519.46	475.26	536.07	551.00	569.29	593.58	490.97	504.22	512.83	NA	359.37	367.51	379.09

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Property Plant And Equipment Net		62.40	63.87	63.54	66.12	68.03	68.00	66.69	59.18	51.04	38.85	28.41	28.24	24.18	23.13	22.30	21.68	19.77	16.24	16.80	15.80	13.87	12.13	11.46	11.81	9.69	7.09	6.08	3.86	3.36
Intangible Assets Net Excluding Goodwill		17.92	18.78	18.85	18.66	18.74	18.71	18.24	18.50	18.09	17.94	16.71	16.49	16.68	16.38	15.55	15.98	15.32	15.16	14.64	14.42	14.03	13.52	12.74	11.97	11.68	11.15	11.04	10.87	10.89
Other Assets Noncurrent		0.50	0.50	0.50	0.65	0.66	0.60	0.60	0.61	0.61	0.61	0.61	0.65	33.45	4.35	10.42	0.21	8.61	8.79	9.19	0.31	10.19	10.73	11.27	0.31	0.31	0.27	0.27	0.21	0.10
Equity Securities Fv Ni		78.90	28.27	44.53	42.21	28.97	39.99	39.71	42.43	32.18	26.89	33.43	36.86	47.58	45.23	6.14	5.30	5.38	2.61	2.25	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Available For Sale Debt Securities Amortized Cost Basis		723.50	554.88	615.47	641.93	433.94	NA	479.54	537.46	566.98	584.97	524.20	455.73	476.23	442.60	393.85	435.10	518.88	473.77	535.01	549.83	567.84	591.94	490.62	505.18	515.16	NA	360.46	368.74	380.28

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Liabilities Current		91.97	80.08	79.40	84.71	53.04	44.63	65.06	63.84	90.03	75.04	60.94	70.74	44.32	45.96	99.93	121.06	70.49	66.45	65.92	66.56	64.31	63.71	73.32	53.85	52.03	101.34	100.33	107.43	106.88
Debt Current		7.75	6.95	7.95	6.33	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Accounts Payable Current		18.77	15.84	16.01	13.91	14.97	14.10	15.34	10.09	14.62	15.75	11.90	14.00	9.13	7.11	7.66	8.95	13.11	10.51	10.31	10.19	8.30	8.99	5.49	3.80	5.98	6.87	6.60	7.38	4.28
Accrued Liabilities Current		25.41	19.56	13.49	23.56	24.47	18.44	15.14	18.73	19.29	16.35	12.61	19.44	22.11	17.33	12.51	17.60	11.38	9.16	7.29	8.99	7.83	6.23	5.71	9.66	5.67	5.48	4.64	3.98	6.50

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Long Term Debt Noncurrent		10.17	12.31	12.49	14.64	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Minority Interest		-2.94	-1.78	-0.34	0.34	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operating Lease Liability Noncurrent		66.49	67.16	66.81	59.02	56.38	54.62	54.77	54.93	22.54	33.94	33.96	33.97	34.09	2.70	9.19	9.74	7.38	7.63	8.04	8.56	9.08	9.65	10.22	NA	NA	NA	NA	NA	NA

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Stockholders Equity		723.84	564.33	612.53	668.80	669.01	678.88	683.58	727.50	722.70	742.34	763.02	733.50	618.86	646.94	583.61	572.44	568.48	570.64	593.00	593.20	610.24	608.09	609.57	521.68	532.27	282.05	290.54	301.37	303.75
Stockholders Equity Including Portion Attributable To Noncontrolling Interest		720.90	562.54	612.19	669.13	669.01	678.88	683.58	727.50	NA	NA	NA	733.50	NA	NA	NA	572.44	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Common Stock Value		0.70	0.62	0.62	0.61	0.61	0.61	0.60	0.60	0.60	0.60	0.60	0.59	0.58	0.58	0.58	0.58	0.57	0.57	0.57	0.57	0.57	0.56	0.56	0.56	0.56	0.47	0.47	0.47	0.47
Additional Paid In Capital		1364.85	1162.73	1144.47	1131.27	1114.38	1101.13	1085.65	1072.13	1058.22	1044.17	1029.06	1017.52	974.51	962.34	951.15	937.52	919.39	908.08	895.86	887.87	877.72	865.16	851.89	845.37	839.13	570.67	566.61	562.02	557.47
Retained Earnings Accumulated Deficit		-643.51	-598.37	-532.40	-464.37	-445.27	-421.00	-399.05	-338.29	-326.24	-293.49	-259.51	-283.10	-356.17	-315.97	-368.22	-365.74	-352.04	-339.49	-304.48	-296.40	-269.49	-259.27	-243.23	-323.28	-305.08	-287.29	-275.44	-259.88	-253.00
Accumulated Other Comprehensive Income Loss Net Of Tax		1.80	-0.65	-0.15	1.29	-0.71	-1.86	-3.62	-6.95	-9.88	-8.94	-7.12	-1.51	-0.07	-0.01	0.10	0.07	0.57	1.48	1.06	1.16	1.44	1.63	0.34	-0.97	-2.34	-1.81	-1.10	-1.24	-1.20
Minority Interest		-2.94	-1.78	-0.34	0.34	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Stock Issued During Period Value New Issues		189.18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	NA	NA	NA	NA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value		12.34	17.19	11.42	NA	12.90	13.56	12.60	NA	12.76	12.60	10.80	NA	8.94	9.35	8.29	NA	8.32	8.23	6.51	NA	9.51	9.30	5.86	5.08	6.12	3.44	3.60	3.45	3.16

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Operating Activities		-26.02	-65.34	-55.26	181.21	-27.28	-38.20	-30.61	-24.43	-1.17	44.27	5.82	61.79	-39.02	-9.65	-29.97	17.08	-3.87	-27.68	9.46	-19.58	-6.48	109.16	-18.73	-16.78	-10.31	-6.67	-3.51	-12.96	-10.55
Net Cash Provided By Used In Investing Activities		-163.46	66.02	32.32	-203.13	45.33	-1.41	48.14	24.55	3.12	-75.64	-71.76	7.86	-38.85	-53.31	38.05	78.78	-50.56	59.41	12.56	15.73	22.06	-102.43	13.67	6.87	5.86	8.94	4.93	9.53	8.55
Net Cash Provided By Used In Financing Activities		187.74	-0.94	0.19	22.98	0.36	1.92	0.92	1.17	1.29	2.51	0.73	32.63	3.23	1.84	5.34	9.59	2.99	4.00	1.47	2.97	3.05	3.97	0.67	1.17	4.15	0.62	0.99	1.10	1.03

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Operating Activities		-26.02	-65.34	-55.26	181.21	-27.28	-38.20	-30.61	-24.43	-1.17	44.27	5.82	61.79	-39.02	-9.65	-29.97	17.08	-3.87	-27.68	9.46	-19.58	-6.48	109.16	-18.73	-16.78	-10.31	-6.67	-3.51	-12.96	-10.55
Net Income Loss		-45.14	-65.96	-68.03	-19.10	-24.27	-21.95	-60.76	-12.04	-32.76	-33.98	23.59	73.06	-40.19	52.25	-2.49	-13.69	-12.55	-35.02	-8.07	-26.91	-10.22	-16.03	80.05	-18.20	3.15	-11.84	-15.56	-6.88	-14.63
Profit Loss		-46.30	-67.41	-68.71	-19.26	-24.27	-21.95	-60.76	-12.04	-32.76	-33.97	23.59	73.06	-40.19	52.25	-2.49	-13.69	-12.55	-35.02	-8.07	-26.91	-10.22	-16.03	80.05	-18.20	3.15	-11.84	-15.56	-6.04	-15.47
Depreciation Depletion And Amortization		3.05	3.02	3.04	3.23	3.14	2.88	2.25	2.16	2.24	2.22	2.18	2.11	1.99	1.75	1.64	1.53	1.45	1.44	1.37	1.23	1.07	1.01	1.00	0.88	0.82	0.61	0.56	0.45	0.41
Increase Decrease In Accounts Payable		2.93	-0.17	2.10	-1.05	0.87	-1.25	5.25	-4.53	-1.13	3.84	-2.10	4.87	2.02	-0.55	-1.29	-4.16	2.60	0.20	0.12	1.88	-0.69	3.51	1.69	-2.19	1.07	0.27	-0.78	3.10	0.40
Share Based Compensation		12.34	17.19	11.42	14.70	12.90	13.56	12.60	12.74	12.76	12.60	10.80	10.39	8.94	9.35	8.29	8.56	8.32	8.23	6.51	7.18	9.51	9.30	5.86	5.08	6.12	3.44	3.60	3.45	3.16

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Investing Activities		-163.46	66.02	32.32	-203.13	45.33	-1.41	48.14	24.55	3.12	-75.64	-71.76	7.86	-38.85	-53.31	38.05	78.78	-50.56	59.41	12.56	15.73	22.06	-102.43	13.67	6.87	5.86	8.94	4.93	9.53	8.55
Payments To Acquire Property Plant And Equipment		1.27	3.03	0.13	0.98	2.83	3.85	10.78	9.97	14.09	12.35	2.09	6.32	2.75	2.28	1.95	3.15	4.70	0.62	2.07	2.91	2.58	1.45	0.41	2.79	1.01	1.48	2.58	0.76	0.49

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Financing Activities		187.74	-0.94	0.19	22.98	0.36	1.92	0.92	1.17	1.29	2.51	0.73	32.63	3.23	1.84	5.34	9.59	2.99	4.00	1.47	2.97	3.05	3.97	0.67	1.17	4.15	0.62	0.99	1.10	1.03

		2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Revenues		10.71	16.96	12.80	44.69	59.16	45.52	18.96	21.61	27.30	30.18	85.50	154.01	19.68	67.45	33.97	41.85	35.37	13.09	32.38	3.52	21.76	19.48	111.94	11.56	29.04	30.15	0.00	12.50	3.50
Alexion Pharmaceuticals Inc		8.60	6.90	9.40	5.20	31.80	11.20	10.50	9.20	7.30	6.70	6.10	5.80	5.80	5.20	5.30	14.70	4.30	3.80	3.30	2.50	5.40	5.10	NA	11.00	9.00	NA	NA	NA	NA
Morpho Sys Incyte		2.10	NA	NA	NA	2.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Shanghai Mabgeek Biotech Co. Ltd.		0.00	1.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Third Party License Agreement		0.00	7.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Vir		0.00	NA	NA	NA	0.00	0.10	1.50	NA	17.80	22.10	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Shanghai Mabgeek Biotech Co. Ltd., Technology License Agreement		0.00	1.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Third Party License Agreement, Patent License Agreement		0.00	7.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Vega Therapeutics Inc., Technology License Agreement		0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Royalty		0.00	NA	NA	8.00	14.50	13.30	13.80	16.20	27.20	30.00	78.70	52.90	13.40	7.30	6.70	6.10	4.50	3.80	3.30	2.50	1.40	1.10	NA	NA	NA	NA	NA	NA	NA
License Agreement		0.00	8.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Milestone		0.00	0.00	0.50	27.50	46.00	10.00	5.00	0.50	0.00	0.00	5.00	7.00	0.00	1.50	12.50	12.40	25.00	0.30	12.50	-0.10	19.30	4.00	NA	11.50	9.00	NA	NA	NA	NA
Non Cash Royalty		10.70	8.50	12.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
		7.09	6.95	3.19	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
		10.71	16.96	12.80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax		10.71	16.96	12.80	44.69	59.16	45.52	18.96	21.61	27.30	30.18	85.50	154.01	19.68	67.45	33.97	41.85	35.37	13.09	32.38	3.52	21.76	19.48	111.94	11.56	29.04	30.15	0.00	12.50	3.50
Alexion Pharmaceuticals Inc		8.60	6.90	9.40	5.20	31.80	11.20	10.50	9.20	7.30	6.70	6.10	5.80	5.80	5.20	5.30	14.70	4.30	3.80	3.30	2.50	5.40	5.10	NA	11.00	9.00	NA	NA	NA	NA
Morpho Sys Incyte		2.10	NA	NA	NA	2.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Shanghai Mabgeek Biotech Co. Ltd.		0.00	1.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Third Party License Agreement		0.00	7.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Vir		0.00	NA	NA	NA	0.00	0.10	1.50	NA	17.80	22.10	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Shanghai Mabgeek Biotech Co. Ltd., Technology License Agreement		0.00	1.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Third Party License Agreement, Patent License Agreement		0.00	7.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Vega Therapeutics Inc., Technology License Agreement		0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Royalty		0.00	NA	NA	8.00	14.50	13.30	13.80	16.20	27.20	30.00	78.70	52.90	13.40	7.30	6.70	6.10	4.50	3.80	3.30	2.50	1.40	1.10	NA	NA	NA	NA	NA	NA	NA
License Agreement		0.00	8.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Milestone		0.00	0.00	0.50	27.50	46.00	10.00	5.00	0.50	0.00	0.00	5.00	7.00	0.00	1.50	12.50	12.40	25.00	0.30	12.50	-0.10	19.30	4.00	NA	11.50	9.00	NA	NA	NA	NA
Non Cash Royalty		10.70	8.50	12.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
		7.09	6.95	3.19	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
		10.71	16.96	12.80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Plots across concepts

Line plots across dimensions of each concept